Purple Biotech LTD. cash flow statement

In fiscal 2020, Purple Biotech LTD.'s operations generated $1.7m of cash; it spent $156,000 on capital projects, leaving free cash flow of $1.5m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Purple Biotech LTD.: cash flow statement, annual
Fiscal year	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020
Cash from operations	−9	−8	−2	2
Depreciation and amortisation	0	0	0	0
Stock-based pay	2	1	1	3
Capital spending	0	0	0	0
Free cash flow	−9	−8	−2	2
Free cash flow after stock pay	−11	−9	−3	−1

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Purple Biotech LTD.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Purple Biotech LTD.